Pancreatic Cancer Research

ResearcherFriedrich-Alexander-Universität Erlangen-NürnbergActive in the last 2 years

Anke Mittelstädt

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0009-1716-3547; OpenAlex author ID A5023715796. Sources: OpenAlex.

Their work

Papers
11 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
16
Papers, trials and grants by year

2022: 1 paper · 2023: 1 paper · 2024: 2 papers · 2025: 4 papers · 2026: 3 papers

Papers 11

  1. Enhancing multidisciplinary tumor board decision-making in pancreatic cancer using cinematic rendering. Co-author DOI 10.1016/j.pan.2025.12.025↗
  2. Immune Cell-Specific and Isoform-Selective Regulation of CD44 in Pancreatic Ductal Adenocarcinoma Links Lymph Node Variant Loss and Exosomal CD44 to Clinical O… Co-author DOI 10.3390/cells15050411↗
  3. Post-Surgical Remodeling of Circulating Monocytes Identifies CD86 Expression on Non-Classical Monocytes as a Prognostic Indicator in Pancreatic Ductal Adenocar… Co-author DOI 10.3390/ijms27115012↗
  4. Impact of Structured Postoperative Surveillance on Survival in Patients with Resected Pancreatic Adenocarcinoma. Co-author DOI 10.3390/cancers17091424↗
  5. The Prognostic Role of Para-Aortic Lymph Node Metastasis in Patients with Resected Pancreatic Adenocarcinoma. Co-author DOI 10.3390/cancers17213418↗
  6. Exosomal CD40, CD25, and Serum CA19-9 as Combinatory Novel Liquid Biopsy Biomarker for the Diagnosis and Prognosis of Patients with Pancreatic Ductal Adenocarc… Co-author DOI 10.3390/ijms26041500↗
  7. Increased Herpesvirus Entry Mediator Expression on Circulating Monocytes and Subsets Predicts Poor Outcomes in Pancreatic Ductal Adenocarcinoma Patients. Co-author DOI 10.3390/ijms26072875↗
  8. CD71 expressing circulating neutrophils serve as a novel prognostic biomarker for metastatic spread and reduced outcome in pancreatic ductal adenocarcinoma pat… First author DOI 10.1038/s41598-024-70916-3↗
  9. Exosomal ROR1 in peritoneal fluid identifies peritoneal disseminated PDAC and is associated with poor survival. Co-author DOI 10.3389/fimmu.2024.1253072↗
  10. Circulating Monocytes Serve as Novel Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma Patients. Co-author DOI 10.3390/cancers15020363↗
  11. Time to Surgery Does Not Affect Overall or Disease-Free Survival of Patients with Primary Resectable PDAC. Co-author DOI 10.3390/jcm11154433↗

Closest collaborators

The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Christian Krautz · 10 shared papers, 2022–2026 · strength 2.08
  2. Robert Grützmann · 10 shared papers, 2022–2026 · strength 2.08
  3. Maximilian Brunner · 10 shared papers, 2022–2026 · strength 2.08
  4. Georg F. Weber · 10 shared papers, 2022–2026 · strength 2.01
  5. Paul David · 7 shared papers, 2023–2026 · strength 1.31
  6. Anne Jacobsen · 6 shared papers, 2022–2026 · strength 1.22
  7. Frederik J. Hansen · 6 shared papers, 2023–2026 · strength 1.08
  8. Isabelle Kuchenreuther · 4 shared papers, 2024–2026 · strength 0.80
  9. Alara Karabiber · 4 shared papers, 2024–2026 · strength 0.79
  10. Lisa-Sophie Arnold · 3 shared papers, 2024–2026 · strength 0.58
  11. Timur Buniatov · 2 shared papers, 2024–2026 · strength 0.43
  12. Yong Jian Zhou · 1 shared paper, 2026 · strength 0.22
  13. Sabine Semrau · 1 shared paper, 2024 · strength 0.15
  14. Yurdagül Zopf · 1 shared paper, 2024 · strength 0.15
  15. Axel Denz · 1 shared paper, 2024 · strength 0.15
  16. Danilo Hackner · 1 shared paper, 2024 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.